Trial intelligence / Profile preview

Yisaipu + methotrexate with or without Tripterygium wilfordii for active rheumatoid arthritis

ChiCTR2400090996Phase 4Not yet recruiting

Sponsor
Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Start
Oct 2024
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label trial of etanercept, methotrexate and tripterygium wilfordii polyglycosides in rheumatoid arthritis (RA) (2 arms), sponsored by Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Primary endpoints: ACR50, ACR20 and 4 more. Planned start Oct 2024; status: not yet recruiting.

02

Drugs

etanerceptmethotrexatetripterygium wilfordii polyglycosides
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on ChiCTR2400090996.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2400090996.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call